On Wednesday, TD Cowen maintained its Hold rating on shares of 10X Genomics (NASDAQ:TXG) with a consistent price target of $18.00. The firm's stance comes in response to the company's release of detailed information on its latest single-cell products aimed at achieving 'single cell for a single cent'. These products include a new high-throughput kit and multiplex capabilities for GEM-X.
The announcement from 10X Genomics highlighted the introduction of these products as part of their effort to reduce costs in single-cell analysis. The new high-throughput kit is designed to enhance the efficiency of processing single cells, while the multiplexing capabilities of GEM-X are intended to offer more versatility in single-cell experiments.
TD Cowen's commentary on the release noted that the new offerings from 10X Genomics are incremental improvements. The analyst believes that these products represent a positive development towards lowering the cost of single-cell analysis, which could potentially increase accessibility for researchers.
The price target of $18.00 set by TD Cowen reflects the firm's valuation of 10X Genomics based on the current market conditions and the potential impact of the new products. Despite the introduction of these products, TD Cowen has not altered its Hold rating, suggesting that the firm is taking a wait-and-see approach regarding the company's performance and market adoption of the new technologies.
Investors and market watchers will likely monitor the uptake of 10X Genomics' new single-cell products and their effect on the company's financials and market position. The Hold rating indicates that while the new products are a step in the right direction, TD Cowen awaits further evidence of their influence on the company's growth trajectory.
In other recent news, 10X Genomics reported a decrease in third-quarter earnings, with total revenue of approximately $151.7 million, marking a 1% decrease from the same period in the previous year. This was largely due to a significant drop in instrument sales, which fell by 46%, contributing to a total of approximately $19.1 million. On a positive note, consumables revenue saw a 10% increase, contributing to a total of approximately $126.2 million.
In response to these figures, several analyst firms maintained their ratings on 10X Genomics. TD Cowen reiterated its Hold rating, while Canaccord Genuity adjusted its price target for the company down to $20.00, yet maintained a Buy rating. Citi also reiterated its Buy rating, while BofA Securities maintained a Neutral rating.
In other recent developments, 10X Genomics announced leadership changes, with Mennah Moustafa appointed as Chief Commercial Officer and Adam Taich as the new CFO. The company also plans to introduce new, cost-effective Single Cell products in the fourth quarter, as well as the launch of the Chromium Xo instrument, a lower-cost option for single-cell analysis. These are some of the recent developments in 10X Genomics.
InvestingPro Insights
Recent data from InvestingPro sheds additional light on 10X Genomics' current financial situation and market performance. The company's market capitalization stands at $1.92 billion, reflecting its position in the genomics technology sector. Despite a revenue growth of 11.14% over the last twelve months, 10X Genomics is currently not profitable, with an adjusted operating income of -$183.54 million for the same period.
InvestingPro Tips highlight that the stock has experienced significant volatility recently. The stock price has taken a substantial hit, declining by 23.55% in the past week and 48.34% over the last six months. This aligns with TD Cowen's cautious Hold rating and $18 price target.
It is worth noting that 10X Genomics holds more cash than debt on its balance sheet, which could provide some financial flexibility as it continues to develop and market its new single-cell products. However, analysts do not anticipate the company to be profitable this year, which may explain the market's current skepticism despite the new product announcements.
For investors seeking a more comprehensive analysis, InvestingPro offers 10 additional tips for 10X Genomics, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.